SureTrader Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs > Cellceutix Corporation (CTIX)

Cellceutix has stated several times that there isn't

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 504
Posts 21,004
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/8/2016 10:04:54 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2016 6:24:52 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/8/2016 4:03:50 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/27/2016 9:57:11 AM
Small Cap Stocks Are Heating up Again, Small Cap Street is Covering (OTCQB: ELTP),(OTCBB: AHIX), (OTCBB: AXXE), (OTCBB: CTIX) "InvestorsHub NewsWire" - 1/26/2016 7:40:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/21/2015 8:19:27 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/18/2015 12:17:11 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/9/2015 4:13:18 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2015 5:26:56 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 11/2/2015 6:07:08 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 10/28/2015 5:26:05 PM
Special Profile Coming and 4 Analyst Reports "InvestorsHub NewsWire" - 7/21/2015 7:00:00 AM
Undervalued and Underexposed NYSE-MKT Stock to be Profiled by Large Media Group and four brief reports "InvestorsHub NewsWire" - 6/15/2015 7:00:00 AM
Special Profile & Four Companies Where Investors are Anticipating Success "InvestorsHub NewsWire" - 6/3/2015 7:00:00 AM
*Special Analyst Alert* and 4 Companies that are Worth a Look "InvestorsHub NewsWire" - 5/13/2015 7:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/11/2015 2:03:16 PM
KarinCA Member Level  Sunday, 12/23/12 12:54:34 PM
Re: Gratefullife post# 15360
Post # of 146260 
Cellceutix has stated several times that there isn't competition to their drug kevetrin. Several companies have been working on it, but, none have achieved the same results. Kevetrin works on both the mutated and wild type p53. The competition seems to only work on the wild form. Kevetrin will end up working on many more cancers since it works on the mutated form.

Kevetrin is an HDAC-2 and HDAC-6 regulators. HDM2 is an inhibitor.

Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. It has also been seen that Kevetrin has anti-angiogenic properties.

See my earlier post including info from company: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82597857

See progressive post of earlier PR dealing with this: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82732988

Also, see search of FDA website for the other companies trials and you will notice HDM2 isn't listed yet.
http://www.clinicaltrial.gov/ct2/results?term=Ascenta+Therapeutics%2C+Inc&Search=Search



KarinCAtrades.com

GLTA... KarinCA ;)

"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist